RxDoctor Payments Data

Ross Hansen

Physician Assistant · Wakefield, NENPI 1679702815

Payments from drug & device makers

What this record shows

This record is dominated by grants: $10,000 of the $12,128 with a category attached, or 82.5%. Medtronic accounts for 82.5% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2024 at $10,366 and has fallen 96.5% since, to $363 in 2025. Among physician assistant clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$12,128in general payments, 2019–2025

Across 150 payments — averaging $80.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$10K
  • AbbVie$451
  • Amgen$296
  • Novo Nordisk$296
  • Astellas Pharma US Inc$187
  • Lilly USA, LLC$133
  • plus $764 from 23 others

What the payments were for

  • Grants$10,00082%
  • Food & beverage$2,12818%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,128 in reported general payments places this provider in the 95th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$32,009
Medicare patients
162
Services billed
2,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin63$49,618
EliquisApixaban91$49,123
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$19,748
JanuviaSitagliptin Phosphate30$16,921
OzempicSemaglutide13$11,798
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$9,080
InvokanaCanagliflozin12$6,617
Repatha SureclickEvolocumab11$5,699
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,250
Atomoxetine Hcl13$2,831
Atorvastatin Calcium230$1,532
Gabapentin120$1,081
Omeprazole103$959
Tamsulosin Hcl93$909
Pantoprazole Sodium116$892

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$94$49,61863 claims
PfizerEliquis$106$49,12391 claims
GSKTrelegy Ellipta, Anoro Ellipta$28$24,99839 claims
MerckJanuvia$15$16,92130 claims
Novo NordiskOzempic$296$11,79813 claims
Johnson & JohnsonInvokana$11$6,61712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Wakefield

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →